Before doctors can prescribe new medications and treatments, they must be shown to be safe and effective. Colorectal cancerclinical trials allow test the effects of new medications on volunteers with colorectal cancer. The researchers follow a strict protocol and use carefully controlled conditions to evaluate the drugs being developed. The evaluation focuses on how well the drug treats colorectal cancer. Researchers also determine its safety and any possible side effects.
Some patients with colorectal cancer are reluctant to take part in clinical trials. One reason is fear of getting no treatment at all. This fear, though, is unwarranted. Patients with colorectal cancer who take part in colorectal cancer trials receive either the most effective therapy available or a treatment that is being evaluated for future use. The cancer drugs being tested may be even more effective than the current colorectal cancer treatment. But a clinical trial is the only way to determine whether they are or not.
Lynch syndrome is a genetic condition that makes people more likely to develop certain cancers. People who have it also have about a 50% to 80% chance of getting colorectal cancer by age 70. They’re also at risk for cancers of the uterus, ovaries, and stomach. And they tend to get cancer at younger ages than other people, often in their 30s and 40s.
Lynch syndrome is sometimes called hereditary non-polyposis colorectal cancer (HNPCC), Muir-Torre syndrome, and Turcot syndrome.
This web site was developed by the nonprofit Coalition of Cancer Cooperative Groups. It is an unbiased cancer clinical trial matching and navigation service that enables patients to search for cancer trials based on disease and location.